BioMarin Boosts Enzyme Therapy Business with Inozyme Acquisition
BioMarin Boosts Enzyme Therapy Business with Inozyme Acquisition BioMarin Pharmaceutical and Inozyme Pharma today announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share…
Extel 2025: WuXi AppTec Recognized with Top Honors
WuXi AppTec Recognized Among Top 10 “Most Honored Companies” in Extel 2025 Asia Executive Team Rankings, Continuing its Global Leadership in Innovation and Drug Discovery Services WuXi AppTec, a leading…
FDA Approves CSL’s Andembry First Once-Monthly Prophylactic HAE Treatment Targeting Factor XIIa
FDA Approves ANDEMBRY (garadacimab-gxii) The First Once-Monthly Prophylactic HAE Therapy Targeting Factor XIIa CSL a leading biotechnology company with a strong track record of developing innovative medicines for patients with…
BMS Presents Transcend FL Data: Breyanzi Shows Durable Responses in Marginal Zone Lymphoma
Bristol Myers Squibb Presents Positive Transcend FL Data Highlighting Durable Responses with Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma Bristol Myers Squibb today announced the first disclosure of the…
Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease
Roche Advances Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease Roche today announced its decision to move forward with Phase III clinical development of prasinezumab — its investigational, humanized…
Lilly Offers All Zepbound Doses via LillyDirect Self-Pay Pharmacy
Lilly to Expand Access to Zepbound: All Approved Doses Now Available in Vials Through LillyDirect’s Self-Pay Pharmacy Solutions Eli Lilly and Company today made a significant announcement aimed at improving…
Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated…
Sarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients
Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update…
QIAGEN and Incyte Partner on Companion Dx for Mutant CALR MPNs
QIAGEN and Incyte Forge Global Collaboration to Develop Companion Diagnostic Panel for Patients With Mutant CALR-Positive Myeloproliferative Neoplasms QIAGEN N.V. and Incyte today announced a significant new collaboration aimed at…
Genmab: Epcoritamab Combo Shows High Response in Transplant-Eligible R/R DLBCL
Genmab Presents Positive Epcoritamab Combination Data in Relapsed or Refractory DLBCL Eligible for Autologous Stem Cell Transplantation Genmab A/S today shared new and highly promising data from its Phase 1b/2…
EAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study
Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals,…
Roche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients
Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of…